Talphera, Inc.
US ˙ NasdaqCM ˙ US00444T2096

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Mark A Wan. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Mark A Wan har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:TLPH / Talphera, Inc. Director 4.592
US:CNCE / Concert Pharmaceuticals Inc 10% Owner 12.301
US:NVRO / Nevro Corp. 0
US:EPOC / Epocrates Inc Director 0
US:LPDX / Liposcience Inc 10% Owner 0
US:THLD / Threshold Pharmaceuticals, Inc. 10% Owner 2.440.202
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Mark A Wan. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb TLPH / Talphera, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i TLPH / Talphera, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2012-12-07 ACRX WAN MARK A 2.364.705 3,3100 118.235 66,2000 7.827.174 227 262.4 23.197.691 296,37
2012-12-07 ACRX WAN MARK A 52.213 3,3100 2.611 66,2000 172.825
2012-05-29 ACRX WAN MARK A 67.543 3,4000 3.377 68,0000 229.646
2012-05-29 ACRX WAN MARK A 3.631 3,4000 182 68,0000 12.345
2012-05-29 ACRX WAN MARK A 208.911 3,4000 10.446 68,0000 710.297
2012-05-29 ACRX WAN MARK A 4.613 3,4000 231 68,0000 15.684

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TLPH / Talphera, Inc. Insider Trades
Insidersalg TLPH / Talphera, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i TLPH / Talphera, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2014-03-10 ACRX WAN MARK A 298.508 12,3600 14.925 247,2000 3.689.559 164 6.3700 -3.594.486 -97,42
2014-03-10 ACRX WAN MARK A 16.049 12,3600 802 247,2000 198.366
2014-03-10 ACRX WAN MARK A 509.520 12,3600 25.476 247,2000 6.297.667
2014-03-10 ACRX WAN MARK A 11.250 12,3600 562 247,2000 139.050
2014-03-07 ACRX WAN MARK A 46.661 12,3882 2.333 247,7640 578.046
2014-03-07 ACRX WAN MARK A 12.186 11,9600 609 239,2000 145.745
2014-03-07 ACRX WAN MARK A 2.508 12,3882 125 247,7640 31.070
2014-03-07 ACRX WAN MARK A 655 11,9600 33 239,2000 7.834
2014-03-07 ACRX WAN MARK A 79.645 12,3882 3.982 247,7640 986.658
2014-03-07 ACRX WAN MARK A 20.800 11,9600 1.040 239,2000 248.768
2014-03-07 ACRX WAN MARK A 1.759 12,3882 88 247,7640 21.791
2014-03-07 ACRX WAN MARK A 459 11,9600 23 239,2000 5.490

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TLPH / Talphera, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Mark A Wan som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2024-06-24 2024-06-24 4 TLPH TALPHERA, INC.
Common Stock
A - Award 2.174 4.592 89,91
2023-12-13 2023-10-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 581 2.418 31,63
2022-07-15 2022-07-15 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 15.500 36.750 72,94
2021-06-17 2021-06-17 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20.000 20.000
2021-06-17 2021-06-17 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 10.000 21.250 88,89
2020-06-16 2020-06-16 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 15.000 15.000
2020-06-16 2020-06-16 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 7.500 11.250 200,00
2019-06-25 2019-06-25 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 7.500 7.500
2019-06-25 2019-06-25 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
A - Award 3.750 3.750
2018-06-14 2018-06-14 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 15.000 15.000
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -126.153 0 -100,00
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -5.713.569 0 -100,00
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -179.962 0 -100,00
2018-05-23 2018-05-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
J - Other -3.347.357 0 -100,00
2017-06-15 2017-06-15 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 15.000 15.000
2016-06-22 2016-06-21 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock (Right to Buy)
A - Award 15.000 15.000
2015-06-24 2015-06-23 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock (Option to Buy)
A - Award 15.000 15.000
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -5.400 12.301 -30,51 12,29 -66.366 151.179
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -244.600 557.126 -30,51 12,29 -3.006.134 6.847.079
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -12.755 29.052 -30,51 12,29 -156.759 357.049
2014-11-20 2014-11-18 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -237.245 540.375 -30,51 12,29 -2.915.741 6.641.209
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series C Preferred Stock
C - Conversion -4.506 0 -100,00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series B Preferred Stock
C - Conversion -15.069 0 -100,00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series A Preferred Stock
C - Conversion -28.090 0 -100,00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series C Preferred Stock
C - Conversion -204.076 0 -100,00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series B Preferred Stock
C - Conversion -682.475 0 -100,00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Series A Preferred Stock
C - Conversion -1.272.187 0 -100,00
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 4.506 47.755 10,42
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 15.069 43.249 53,47
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 28.090 28.180 31.211,11
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 204.076 2.162.814 10,42
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 682.475 1.958.738 53,47
2014-11-12 2014-11-12 4 NVRO NEVRO CORP
Common Stock
C - Conversion 1.272.187 1.276.263 31.211,65
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8.242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4.256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8.242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4.256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8.242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4.256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8.242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4.256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8.242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4.256
2014-11-05 3 NVRO NEVRO CORP
Common Stock
8.242
2014-11-05 3 NVRO NEVRO CORP
Common Stock
4.256
2014-07-25 2014-07-24 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 15.000 15.000
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -11.250 126.153 -8,19 12,36 -139.050 1.559.251
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -509.520 5.713.569 -8,19 12,36 -6.297.667 70.619.713
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -16.049 179.962 -8,19 12,36 -198.366 2.224.330
2014-03-11 2014-03-10 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -298.508 3.347.357 -8,19 12,36 -3.689.559 41.373.333
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -459 137.403 -0,33 11,96 -5.490 1.643.340
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -1.759 137.862 -1,26 12,39 -21.791 1.707.862
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -20.800 6.223.089 -0,33 11,96 -248.768 74.428.144
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -79.645 6.243.889 -1,26 12,39 -986.658 77.350.546
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -655 196.011 -0,33 11,96 -7.834 2.344.292
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -2.508 196.666 -1,26 12,39 -31.070 2.436.338
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -12.186 3.645.865 -0,33 11,96 -145.745 43.604.545
2014-03-11 2014-03-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
S - Sale -46.661 3.658.051 -1,26 12,39 -578.046 45.316.667
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -391.359 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -1.956.794 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -1.467.595 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -8.641 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -43.206 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -32.405 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 101.264 801.726 14,46 14,00 1.417.696 11.224.164
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 2.236 17.701 14,46 14,00 31.304 247.814
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 69.267 700.462 10,97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 346.335 631.195 121,58
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 259.751 284.860 1.034,49
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 1.529 15.465 10,97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 7.647 13.936 121,59
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 5.735 6.289 1.035,20
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -379.592 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -1.897.959 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -1.423.469 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock
C - Conversion -20.408 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock
C - Conversion -102.041 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock
C - Conversion -76.531 0 -100,00
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 98.219 777.620 14,46 14,00 1.375.066 10.886.680
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
P - Purchase 5.281 41.807 14,46 14,00 73.934 585.298
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 67.184 679.401 10,97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 335.922 612.217 121,58
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 251.941 276.295 1.034,50
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 3.612 36.526 10,97
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 18.060 32.914 121,58
2014-02-21 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
C - Conversion 13.545 14.854 1.034,76
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.217
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.772
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.017
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
26.972
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
50.017
2013-09-13 2013-09-12 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 15.000 15.000
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -11.790 0 -100,00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -11.790 0 -100,00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -15.720 0 -100,00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
D - Sale to Issuer -15.720 0 -100,00
2013-03-13 2013-03-12 4 EPOC EPOCRATES INC
Common Stock
D - Sale to Issuer -1.655.329 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series F Convertible Preferred Stock
C - Conversion -25.261 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series F Convertible Preferred Stock
C - Conversion -534.339 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series E Convertible Preferred Stock
C - Conversion -41.509 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series E Convertible Preferred Stock
C - Conversion -878.030 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock
C - Conversion -69.183 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock
C - Conversion -1.463.385 0 -100,00
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
P - Purchase 9.705 83.739 13,11 9,00 87.345 753.651
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
P - Purchase 205.295 1.771.347 13,11 9,00 1.847.655 15.942.123
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
C - Conversion 72.646 74.034 5.233,86
2013-01-31 2013-01-30 4 LPDX LIPOSCIENCE INC
Common Stock
C - Conversion 1.536.688 1.566.052 5.233,24
2013-01-24 3 LPDX LIPOSCIENCE INC
Common Stock
29.364
2013-01-24 3 LPDX LIPOSCIENCE INC
Common Stock
1.388
2012-12-11 2012-12-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 52.213 139.621 59,73 3,31 172.825 462.146
2012-12-11 2012-12-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 2.364.705 6.323.534 59,73 3,31 7.827.174 20.930.898
2012-08-14 2012-08-13 4 EPOC EPOCRATES INC
Non-Qualified Stock Option (right to buy)
A - Award 11.790 11.790
2012-07-26 2012-07-24 4 ACRX ACELRX PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award -12.500 12.500 -50,00
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 4.151 4.151 0,12 519 519
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 188.020 188.020 0,12 23.502 23.502
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 3.268 3.268 0,12 408 408
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 60.789 60.789 0,12 7.599 7.599
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 4.613 87.408 5,57 3,40 15.684 297.187
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 208.911 3.958.829 5,57 3,40 710.297 13.460.019
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 3.631 199.174 1,86 3,40 12.345 677.192
2012-06-06 2012-05-29 4/A ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 67.543 3.704.712 1,86 3,40 229.646 12.596.021
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 4.151 4.151 0,12 519 519
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 188.020 188.020 0,12 23.502 23.502
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 3.268 3.268 0,12 408 408
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock
P - Purchase 60.789 60.789 0,12 7.599 7.599
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 4.613 87.408 5,57 3,40 15.684 297.187
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 208.911 3.958.829 5,57 3,40 710.297 13.460.019
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 3.631 199.174 1,86 3,40 12.345 677.192
2012-05-31 2012-05-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock
P - Purchase 67.543 3.704.712 1,86 3,40 229.646 12.596.021
2006-03-07 2006-03-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
S - Sale -1.000.000 2.440.202 -29,07 14,50 -14.500.000 35.382.929
2005-02-10 2005-02-09 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
P - Purchase 11.939 175.491 7,30 7,00 83.573 1.228.437
2005-02-10 2005-02-09 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
P - Purchase 222.059 3.264.711 7,30 7,00 1.554.413 22.852.977
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -154.607 0 -100,00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -2.875.696 0 -100,00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -114.750 0 -100,00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -2.135.250 0 -100,00
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 93.877 163.552 134,74
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 1.746.126 3.042.652 134,68
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 69.675 69.675
2005-02-03 2005-02-03 4 THLD THRESHOLD PHARMACEUTICALS INC
Common Stock
C - Conversion 1.296.526 1.296.526
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)